Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) shares reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $1.39 and last traded at $1.49, with a volume of 17383 shares changing hands. The stock had previously closed at $1.79.
A number of research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Neovasc from a “hold” rating to a “sell” rating in a research note on Tuesday, August 14th. ValuEngine raised shares of Neovasc from a “hold” rating to a “buy” rating in a research note on Saturday, September 22nd.
The stock has a market capitalization of $37.17 million, a P/E ratio of -0.04 and a beta of 1.44.
Several hedge funds have recently added to or reduced their stakes in NVCN. Renaissance Technologies LLC raised its position in shares of Neovasc by 837.5% during the 2nd quarter. Renaissance Technologies LLC now owns 53,754,832 shares of the medical equipment provider’s stock worth $2,300,000 after buying an additional 48,020,900 shares in the last quarter. Gagnon Advisors LLC raised its position in shares of Neovasc by 2,416.2% during the 2nd quarter. Gagnon Advisors LLC now owns 46,032,686 shares of the medical equipment provider’s stock worth $1,970,000 after buying an additional 44,203,204 shares in the last quarter. Gagnon Securities LLC raised its position in shares of Neovasc by 350.7% during the 2nd quarter. Gagnon Securities LLC now owns 19,120,325 shares of the medical equipment provider’s stock worth $818,000 after buying an additional 14,878,428 shares in the last quarter. Finally, Capital Research Global Investors bought a new stake in shares of Neovasc during the 3rd quarter worth about $1,917,000.
COPYRIGHT VIOLATION NOTICE: This news story was published by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.wkrb13.com/2018/11/16/neovasc-nvcn-hits-new-52-week-low-at-1-39.html.
About Neovasc (NASDAQ:NVCN)
Neovasc Inc, a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products.
Featured Article: What are the risks of holding treasury bonds?
Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.